2. Academic Validation
  3. Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist

Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist

  • Bioorg Med Chem. 2023 Apr 15:84:117258. doi: 10.1016/j.bmc.2023.117258.
Willem F J Karstens 1,  Wiro M B P Menge 2,  Gijs Martens 2,  Sanne J N Op Het Veld 2,  Jacobus Th H van Eupen 2,  Marco Demon 2,  Tanja A E van Achterberg 2,  Monica J Arisse-Thijssen 2,  Ellen W H Santegoeds-Lenssen 2,  Miranda M C van der Lee 2,  Ruud Ubink 2,  Roel J Arends 2,  Aloys Sesink 2,  Marion Blomenröhr 3,  C Marco Timmers 2
Affiliations

Affiliations

  • 1 Byondis BV, Microweg 22, 6545 CM Nijmegen, The Netherlands. Electronic address: willemjan.karstens@byondis.com.
  • 2 Byondis BV, Microweg 22, 6545 CM Nijmegen, The Netherlands.
  • 3 Byondis BV, Microweg 22, 6545 CM Nijmegen, The Netherlands; Present address: Bone-Tech BV, Kloosterstraat 9, 5349 AB Oss, The Netherlands.
PMID: 37001244 DOI: 10.1016/j.bmc.2023.117258
Abstract

The thyrotropin receptor (TSH-R) regulates the thyroid gland and is normally activated by thyrotropin. In patients with Graves' disease, TSH-R is also stimulated by stimulatory TSH-R autoantibodies leading to hyperthyroidism. In this paper, we describe the discovery of SYD5115 (67), a novel small molecule TSH-R antagonist with nanomolar potency. SYD5115 also blocks stimulating antibody induced synthesis of the thyroid hormone thyroxine (T4) in vivo, after a single oral dose. During optimization, several issues had to be addressed such as the low metabolic stability and the potential mutagenicity of our first series of compounds.

Keywords

GPCR-antagonist; Graves’ disease; Small molecule antagonist; TSH-R antagonist; Thyroid stimulating hormone receptor; Thyrotropin receptor.

Figures
Products